Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Nalbuphine Versus Midazolam in Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: -~* Female gender .~* Age : 18 - 40 years old .~* Physical status : ASA II .~* Elective cesarean section~Exclusion Criteria:~* - Patient refusal .~* History of hypertension or cardiac diseases .~* Psychiatric disorders .~* Coagulopathy .~* Allergy to study drugs .~* Contraindication to spinal anesthesia .~* Failure of spinal anesthesia .

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- bupivacaine (Type: EXPERIMENTAL): 12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
- nalbuphine (Type: ACTIVE_COMPARATOR): 12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
- midazolam (Type: ACTIVE_COMPARATOR): 12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .

Based on this trial design, predict the completion outcome and termination type (if applicable).